Free Trial
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$0.15
-1.8%		$0.23
$0.13
▼
$3.28
$2.14M6.117.32 million shs419,046 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-0.26%+2.13%-17.54%-67.98%-95.27%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$0.15
-1.8%		$0.23
$0.13
▼
$3.28
$2.14M6.117.32 million shs419,046 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-0.26%+2.13%-17.54%-67.98%-95.27%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
2.25
Hold$2.801,754.30% Upside

Current Analyst Ratings Breakdown

Latest VVOS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$17.44M0.12N/AN/A($0.16) per share-0.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-$21.17M-$1.90N/AN/AN/A-122.00%-2,325.64%-102.01%11/18/2026 (Estimated)

Latest VVOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-$0.41-$0.31+$0.10-$0.31$5.63 million$5.15 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/A
0.21
0.21

Institutional Ownership

CompanyInstitutional Ownership
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
26.35%

Insider Ownership

CompanyInsider Ownership
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
2.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
26813.90 million13.60 millionOptionable

Recent News About These Companies

Vivos Therapeutics targets $3.6 million in annual cost reductions as revenue growth initiatives accelerate
September 29, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/vivos-therapeutics-targets-3-6-million-in-annual-cost-reductions-as-revenue-growth-initiatives-accelerate/ar-AA2dd3WM
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370865/0/en/vivos-therapeutics-reports-progress-in-material-cost-reductions-and-revenue-growth-initiatives.html
Head-To-Head Contrast: Vivos Therapeutics (NASDAQ:VVOS) versus ResMed (NYSE:RMD)
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31054696
Vivos Therapeutics Announces Material Debt Reduction
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357678/0/en/vivos-therapeutics-announces-material-debt-reduction.html
Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference
September 1, 2026  |  newsfilecorp.comN
Vivos Therapeutics Advances South Florida Sleep Center With South Palm Cardiovascular Partnership
August 28, 2026  |  rttnews.comhttps://www.rttnews.com/3686483/vivos-therapeutics-advances-south-florida-sleep-center-with-south-palm-cardiovascular-partnership.aspx
Vivos Therapeutics Announces Definitive Agreements With South Palm Cardiovascular Associates to Launch South Florida Sleep & Airway Medicine Center
August 28, 2026  |  quiverquant.comQ
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center
August 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/28/3352691/0/en/vivos-therapeutics-and-south-palm-cardiovascular-associates-sign-definitive-agreements-to-launch-regional-sleep-testing-and-treatment-center.html
Vivos Therapeutics Reports 212% Increase in Nevada Sleep & Airway Medicine Center Referrals Ahead of Henderson Facility Opening
August 25, 2026  |  quiverquant.comQ
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers
August 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3350463/0/en/vivos-therapeutics-reports-record-new-patient-referrals-at-its-nevada-sleep-airway-medicine-centers.html
Vivos Therapeutics Opens New Henderson Sleep Center, Expects Capacity to More Than Double to Over $10 Million Annually
August 20, 2026  |  quiverquant.comQ
Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348540/0/en/vivos-therapeutics-opens-new-sleep-testing-and-treatment-facility-in-nevada-to-meet-rapidly-growing-patient-demand-for-sleep-apnea-testing-and-treatment.html
Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts
August 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/vivos-therapeutics-shares-slide-after-q2-revenue-falls-short-of-forecasts/ar-AA2aisUN
Vivos Therapeutics, Inc: Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update
August 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69320784-vivos-therapeutics-inc-vivos-therapeutics-reports-second-quarter-2026-financial-results-and-provides-operational-update-399.htm
Vivos Therapeutics, Inc. (VVOS) Q2 2026 Earnings Call Transcript
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936959-vivos-therapeutics-inc-vvos-q2-2026-earnings-call-transcript
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates
August 14, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975352/vivos-therapeutics-inc-vvos-reports-q2-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2975352
Vivos Therapeutics Reports 35% Quarterly Revenue Growth, Rising Patient Demand and Second Quarter 2026 Results
August 14, 2026  |  quiverquant.comQ
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345627/0/en/vivos-therapeutics-reports-second-quarter-2026-financial-results-and-provides-operational-update.html
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345341/0/en/vivos-therapeutics-schedules-release-of-second-quarter-2026-financial-results-and-conference-call.html
Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations
August 11, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vivos-therapeutics-expands-greenway-health-partnership-to-deploy-ai-enabled-platform-across-all-clinical-and-revenue-operations-1036440833

New MarketBeat Followers Over Time

Media Sentiment Over Time

Vivos Therapeutics stock logo

Vivos Therapeutics NASDAQ:VVOS

$0.15 0.00 (-1.76%)
Closing price 04:00 PM Eastern
Extended Trading
$0.15 +0.00 (+0.66%)
As of 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas